Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin intravenous - Maas Biolab/Abliva

Next Previous
Drug Profile

Ciclosporin intravenous - Maas Biolab/Abliva

Alternative Names: CicloMulsion; Ciclosporin-A; Cyclosporin - Maas Biolab; Cyclosporin-A; Mitogard; Neuro-STAT®; NeuroSTAT; OWL-1410

Latest Information Update: 22 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Maas Biolab; NeuroVive Pharmaceutical
  • Developer Abliva; Defense Threat Reduction Agency; Maas Biolab; NeuroVive Pharmaceutical; Skane University Hospital; Walter Reed Army Institute of Research
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Cyclophilin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Traumatic brain injuries
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Traumatic brain injuries
  • Discontinued Acute kidney injury; Amyotrophic lateral sclerosis; Poisoning; Reperfusion injury

Most Recent Events

  • 17 Nov 2023 Ciclosporin intravenous licensed to Owl Therapeutics worldwide
  • 15 Jun 2020 Abliva plans a phase II trial for Traumatic brain injuries
  • 28 May 2020 NeuroVive Pharmaceutical is now called Abliva
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top